Efficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae

The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. It will also estimate the impact of non-invasive neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae.The main question it aim to answer is: - Is non-invasive neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of Covid-19. Researchers will compare non-invasive neuromodulation to a placebo (treatment with the machine turned off). Participants will: * Be evaluated before starting treatment. * Be evaluated 3 weeks after. * Be evaluated at 5 weeks, or 15 sessions or completion of treatment. * Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.